Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSJD5037 is an inverse agonist of peripheral cannabinoid 1 (CB1) receptors (Ki = 0.35 nM).1 It displays >700-fold selectivity for CB1 over CB2, >1,000-fold selectivity over a panel of 70 receptors, transporters, and ion channels, and low blood-brain barrier penetrance.1,2 JD5037 is orally bioavailable and reduces food intake, body weight, and hormonal/metabolic abnormalities in diet-induced obese mice.1,3 JD5037 reverses hyperphagia, reduces body weight, and improves metabolic parameters in Magel2-null mice, a model of Prader-Willi syndrome.4
WARNING This product is not for human or veterinary use.
1. Peripheral cannabinoid-
2. JD-
3. Hepatic cannabinoid-
4. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-